Established in September 2020, Shanghai ConFlow MedTech Co., Ltd., known as "ConFlow MedTech," stands as a distinguished high-tech company dedicated to research and development, manufacturing, and industrialization of innovative cardiovascular medical devices. Through continuous independent research and development and clinical application of cutting-edge technologies, we are committed to becoming a world-class innovative product manufacturer with international influence.
Nestled in the heart of Songjiang Science and Technology City, Shanghai Lingang Group, our headquarters occupies a spacious 2,200-square-meter complex. This facility boasts a pristine environment featuring a 10k-Grade clean workshop, well-equipped laboratories, machining platforms, and modern office spaces. Furthermore, it features state-of-the-art hardware facilities that play a pivotal role in bolstering the company's R&D endeavors, as well as expediting project progress.
ConFlow MedTech has gained strong support and praise from government bodies and institutional investors since its inception. We've secured significant funding of nearly RMB100 million from esteemed institutions like TigerYeah Capital, Taikun Fund, and Yuanlai Yuanqi Venture Capital. Furthermore, our company has earned recognition through various certifications, including those for innovation-oriented SMEs, science and technology-based enterprises, and specialized and sophisticated SMEs in Shanghai. The company's medical-engineering transformation and innovative research and development business are thriving.
Diving into the realm of medical-engineering transformation and pioneering research and development, the company has achieved remarkable growth. Its product portfolio now encompasses a wide spectrum of offerings, spanning heart failure treatment, interventional therapy for congenital heart disease, valve products, and peripheral vascular therapy devices.
• World's first atrial septal shunt features a polymer membrane for rapid endothelialization and dual recycling.
• Innovative elliptical disc design reduces implant size.
• Available in multiple aperture sizes (5mm, 7mm, 9mm, and 11mm) to better suit patient treatment requirements.
• The 8-10F delivery system incorporates a unique bend angle for simplified surgical procedures.
• The concluder’s left atrial surface departs from the conventional disc-shaped structure, opting for a clamp arm design, thereby markedly diminishing the likelihood of left atrial implantation and instrument thrombosis.
• Distinguished by its distinctive design, the device features a compact implant size to minimize interference with subsequent atrial septal puncture procedures.
• Our product model boasts a variety of specifications tailored to address complex patent foramen ovale (PFO) cases.
• Our innovative edge enhancement design not only effectively addresses valve regurgitation but also mitigates the risk of valve stenosis.
• Our product line-up includes diverse specifications, offering a wide range of treatment choices.
• The tibiofemoral vein's double-layer controlled bending delivery system allows for dynamic angle adjustments of the instrument, facilitating surgical precision for healthcare professionals.
As we bid farewell to the old and embrace the new, ConFlow MedTech is celebrating significant milestones. We are thrilled to announce the successful closure of Round A financing, securing nearly 60 million RMB. This financing round is led by Tai Yu Ankang and co-invested by Tai Kun Fund.
The funds from this round will primarily be allocated towards advancing ConFlow MedTech's research projects through preclinical and registered clinical trials. Furthermore, they will fully support independent R&D of newly launched products. This financial support will play a pivotal role in advancing the R&D of innovative products at ConFlow MedTech.
We embrace the corporate philosophy of "Pride in progress, pursuing excellence." We attract and develop top talents to help them reach their full potential. Our company provides comprehensive talent development programs for employees at all career levels, along with diverse learning opportunities through multiple channels.
Furthermore, we align our talent strategy with our business goals to establish a talent pipeline and succession plan. This ensures we nurture individuals capable of meeting the company's future requirements and strengthening our core competitiveness.
